Background: A major impediment in the treatment of ovarian cancer is the relapse of 9 platinum-resistant tumors, which occurs in approximately 25% of patients. A better 1 0
Differential Gene Expression Analysis: The Limma 25 package in Bioconductor 26 was used to 1 0 8 identify differentially expressed genes between chemo-sensitive and resistant groups using 1 0 9
linear models. The false discovery rate (FDR) method was employed as a measure for 1 1 0 multiple testing correction to control for type I error. Age at diagnosis and stage of tumor 1 1 1
were included as covariates in this analysis (Supplemental Data 2).
2
Weighed Gene Co-expression Network Analysis (WGCNA): We performed hierarchical 1 1 3 clustering of genes using the R package WGCNA 19 , which groups genes based on their 1 1 4 similarity in expression. This was achieved by first creating a similarity matrix using Pearson 1 1 5 correlations of expression among all genes. The resulting matrix was raised to a power of 9, 1 1 6
as suggested by the soft-thresholding power estimation plot (Supplemental Figure 1) . This 1 1 7
assumes that raising the correlation matrix to a power will enrich differences between weak 1 1 8 and strong signals, allowing for better quantification of gene-gene interactions. In addition, 1 1 9 because information between two genes are often too weak and noisy to interpret, similarity 1 2 0 matrix is transformed to Topological Overlap Matrix (TOM), where strength of association 1 2 1 between a pair of genes is reinforced by the common neighbors shared by them. associated with resistance to chemotherapy (FDR adjusted p-value < 0.05; Figure 1) . In 1 9 7 addition, 606 probes mapping to 521 unique genes were nominally correlated with 1 9 8 chemotherapy response (unadjusted p-value < 0.05; Supplemental Table 1 ). The Kaplan-1 9 9
Meier survival plotter demonstrated that low expression of VCP is associated with poor 2 0 0 progression-free survival (p = 0.015) and shorter median survival time (Figure 2) in an 2 0 1 independent ovarian serous cancer cohort following treatment with platinum antineoplastic 2 0 2 agents. Functional annotation analysis showed that the 521 genes were enriched for numerous 
0 9
The hierarchical clustering of genes using WGCNA resulted in 86 unique modules of 2 1 0 co-expressed genes (Supplemental Table 2 ). Each module was assessed for association with patients (Supplemental Figure 4) . The five significant modules were annotated using 2 1 8 DAVID, which identified gene enrichment for biological pathways including apoptosis, 2 1 9 1 2 negative regulation of the Wnt signaling pathway, transcription, immune responses, and DNA 2 2 0 double-strand break processing involved in repair via single-strand annealing. GeneMANIA 2 2 1 analysis showed that genes in these modules were previously reported in 49 publications, 2 2 2 some of which documented associations with oncogenic pathways and chemotherapeutic 2 2 3 outcomes. Our search of these genes in the gene-drug interaction database (DGIdb) found 2 2 4 that 35 were associated with chemotherapeutic agents such as carboplatin and paclitaxel.
5
Furthermore, we identified over-represented conserved transcription factor binding sites 2 2 6 located in genes from each module. A detailed list of functional annotations, transcription 2 2 7 factors and pathways related to gene modules can be found in Supplemental Data 6.
8
Our GWAS of SNPs did not identify any variants correlated for platinum 256 in BRCA2, we identified 34 SNPs in BRCA2 and 1 SNP in BRCA1 that were significantly 2 3 6 associated with chemotherapy response ( Supplemental Table 3 ).
3 7
Next, SNPs were tested for correlation with expression of the 606 differentially In this manuscript, we identified novel genes and gene networks correlated with variable 2 4 4 response to platinum-based chemotherapy in HGSOC patients. Using a univariate analysis 2 4 5 approach, we identified a differentially expressed locus encoding the valosin-containing 2 4 6 protein (VCP) associated with sensitivity to platinum-based chemotherapy. In addition, we 2 4 7 applied a multivariate, co-expression analysis method for identifying groups of 2 4 8
interconnected genes that could contribute to common biological pathways. This method 2 4 9
identified 5 clusters of co-expressed genes nominally correlated with chemo-response, one of 2 5 0 which remained significant after correction of multiple testing. Genes in these modules have 2 5 1 been annotated to be associated with biological pathways such as apoptosis, transcription, 2 5 2 immune response, negative regulation of the Wnt signaling pathway and DNA double-strand 2 5 3 break processing involved in repair via single-strand annealing.
5 4
The most significantly associated probe identified in the DGE analysis was for a 2 5 5 gene encoding Valosin-containing protein (VCP, p = 3.91E-06). We have confirmed that this factor, which may be used as a novel potential target for ovarian cancer therapies 3 0 9
The other four co-expression modules, which we were also able to replicate in an 3 1 0 independent cohort, include genes known to be involved in oncogenic process and drug 3 1 1 response outcomes. For example, the orangered4 module is composed of genes that are 3 1 2 critical for regulation of immune response, which have been shown to play a role in 3 1 3 1 6 chemotherapy response in HGSOC. 14, 15 platinum-based chemotherapy response in prior studies. In addition, we report potentially 3 4 4 regulatory variants in the BRCA2 gene correlated with chemotherapy response and the 3 4 5 expression of genes that determine cholesterol levels. Moreover, we identified a novel group 3 4 6 of potentially co-regulated genes on chromosome 9 that are correlated with platinum 3 4 7 resistance using a machine-learning algorithm. In addition, genes from this module are also 3 4 8
involved in protein processing in the endoplasmic reticulum. This manuscript supports earlier 3 4 9 studies which implicated VCP and BRCA2 genes in chemotherapy response. We also 3 5 0 identified regulatory variants in BRCA2 and additional genes co-regulated with VCP on 3 5 1 chromosome 9 that also contribute to protein removal in the ER. Findings from our study 3 5 2 could facilitate genetic testing through the identification of gene signatures that may predict 3 5 3 chemotherapy response as well as lead to novel drug targets, given a better understanding of 3 5 4 the biological mechanisms underlying chemotherapy response. 
